CJC-1295 Research Peptide: GHRH Signalling Studies UK Laboratory Guide
CJC-1295 has become one of the most widely studied synthetic peptide analogues in modern endocrine and metabolic research. As scientific interest in growth hormone-releasing hormone (GHRH) signalling pathways continues to expand across the UK research community, CJC-1295 has established itself as a highly relevant laboratory compound valued for its structural stability, extended receptor interaction profile, and suitability for controlled in-vitro and regulated in-vivo experimental systems.
At Elevr, we supply high-purity CJC-1295 strictly for laboratory and research use. This guide is designed to help UK-based researchers understand what CJC-1295 is, how it has been studied in controlled laboratory environments, and what to look for when sourcing a research-grade compound.
Important Disclaimer: All information in this article relates strictly to laboratory and in-vitro research. CJC-1295 supplied by Elevr is intended for research purposes only. It is not approved for human or veterinary use, supplementation, or any therapeutic, diagnostic, or cosmetic application. It has not been evaluated by the MHRA or any regulatory authority for clinical use.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — a naturally occurring peptide produced in the hypothalamus that plays a key role in the regulation of growth hormone secretion from the anterior pituitary gland.
Structurally, CJC-1295 is based on the first 29 amino acids of endogenous GHRH (GHRH 1-29), with specific modifications designed to improve its stability and receptor interaction profile in experimental systems. The most significant of these modifications is the incorporation of a Drug Affinity Complex (DAC) a technology that enables the peptide to bind to endogenous albumin in biological models, significantly extending its half-life compared to native GHRH and unmodified analogues.
CJC-1295 without DAC (also referred to as Modified GRF 1-29 or Mod GRF 1-29) is a related compound that shares the same amino acid sequence but lacks the albumin-binding modification. This results in a considerably shorter half-life in experimental systems approximately 30 minutes compared to the 6 to 8 day half-life observed with CJC-1295 DAC in laboratory research models. Both forms are studied in research settings, with selection depending on the specific experimental protocol requirements.
As a research compound, CJC-1295 is supplied as a lyophilised white powder in a sealed glass research vial, verified to ≥99% purity via HPLC analysis, making it suitable for controlled laboratory experimental systems.
How Does CJC-1295 Work in Research Models?
In laboratory settings, CJC-1295 is studied primarily for its interaction with GHRH receptors (GHRH-R) located in the anterior pituitary gland. Research has examined how CJC-1295 binding to these receptors influences downstream intracellular signalling cascades in controlled experimental systems.
The key molecular mechanisms investigated in research models include:
GHRH-R Binding and Gs Protein Activation In vitro receptor binding studies have demonstrated CJC-1295's high affinity interaction with GHRH-R across multiple cell model systems. Upon receptor binding, CJC-1295 activates the Gs protein pathway, leading to adenylyl cyclase stimulation and subsequent cyclic adenosine monophosphate (cAMP) elevation in experimental models.
PKA and CREB Pathway Activation The cAMP cascade activated by CJC-1295 in research models stimulates protein kinase A (PKA), which in turn phosphorylates downstream transcription factors including CREB (cAMP response element-binding protein). Laboratory studies using fluorescence-based cAMP assays have consistently demonstrated dose-dependent increases in intracellular cAMP levels following CJC-1295 treatment in GHRH-R-expressing cell lines.
Albumin Binding and Extended Half-Life A defining characteristic of CJC-1295 DAC in laboratory research is its ability to bind to endogenous albumin through the DAC modification. This albumin-binding property extends the compound's half-life to approximately 6 to 8 days in research models a significant distinction from native GHRH, which is rapidly degraded by enzymatic activity. This extended stability makes CJC-1295 a practical tool for research protocols requiring sustained receptor engagement over extended observation windows.
GH and IGF-1 Signalling Research has examined how CJC-1295-driven GHRH-R activation influences growth hormone synthesis and release patterns in pituitary cell models, and how this relates to downstream IGF-1 pathway activity. Studies using controlled experimental systems have investigated the relationship between CJC-1295 treatment, pulsatile GH release patterns, and subsequent IGF-1 production in laboratory models.
Key Research Areas What Scientists Have Investigated
1. GH Secretion and Pituitary Signalling Research
The most extensively studied area of CJC-1295 research involves its role in growth hormone secretion studies. Published investigations have examined how CJC-1295 influences GH release patterns in controlled laboratory and clinical research settings.
A notable peer-reviewed study published in the Journal of Clinical Endocrinology and Metabolism examined how CJC-1295 influenced growth hormone and IGF-1 levels in healthy adults over an extended observation period findings that have been widely cited in subsequent laboratory research. This study demonstrated that the sustained GHRH-R stimulation achievable with CJC-1295 DAC produces prolonged GH and IGF-1 signalling responses in research subjects, making it a valuable reference compound for endocrine pathway studies.
It is important to note that this and similar studies were conducted in regulated clinical research environments and do not constitute evidence of therapeutic benefit for general use.
2. Metabolic Research Models
Laboratory investigations have explored CJC-1295 in the context of metabolic research. Through its influence on GH/IGF-1 signalling in experimental models, CJC-1295 has been studied in relation to protein synthesis pathways, lipid metabolism models, and glucose regulation research in controlled laboratory systems.
Research in this area has used CJC-1295 as a tool compound to investigate how sustained GHRH-R activation affects metabolic signalling endpoints in cell culture and preclinical research environments. This makes it a relevant compound for UK researchers working in metabolic biology, endocrinology, and body composition research models.
3. Cellular Ageing and Longevity Research Models
CJC-1295 has also featured in laboratory research examining cellular ageing models. Published investigations have explored how sustained GH/IGF-1 signalling pathways as studied through GHRH analogues including CJC-1295 interact with processes relevant to cell senescence, mitochondrial function, and metabolic maintenance in experimental systems.
Researchers have investigated the relationship between moderate GHRH-R activation and tissue integrity maintenance in ageing cell models. This research remains at the preclinical stage and no therapeutic conclusions can be drawn from these laboratory findings.
4. Neurological and Cognitive Research Models
More recently, published research has examined CJC-1295 alongside GHRP compounds in models exploring neurological function. Laboratory investigations have studied how GHRH signalling influences neuroprotective pathways and cognitive function models in controlled experimental systems.
Combined investigations using CJC-1295 with other research compounds have explored potential synergistic effects on downstream signalling in neurological cell models an area of growing interest for UK researchers working in neuroscience and cognitive biology research.
5. CJC-1295 and Ipamorelin Combined Research Models
One of the most actively investigated research areas in the UK involves the combined use of CJC-1295 and ipamorelin in laboratory experimental systems. These two compounds operate through complementary but distinct mechanisms in research models CJC-1295 acting via GHRH-R, and ipamorelin acting via ghrelin receptors making their combined investigation of interest for researchers studying synergistic GH secretagogue pathways.
Published preclinical literature has examined how this combination influences GH release patterns, metabolic endpoints, and downstream transcription factor activity in controlled laboratory systems. The complementary receptor mechanisms of these two compounds have made their combined study a notable area of research interest for laboratories investigating GH signalling biology.
Elevr supplies both CJC-1295 and ipamorelin as separate research compounds for use in controlled laboratory environments.
CJC-1295 With DAC vs Without DAC What Researchers Should Know
A common question for UK researchers working with CJC-1295 concerns the distinction between the DAC and non-DAC forms of this compound.
CJC-1295 With DAC The DAC modification enables albumin binding, extending the compound's half-life to approximately 6 to 8 days in research models. This form is studied in research protocols requiring sustained, continuous GHRH-R engagement over an extended experimental window. It produces a prolonged, relatively steady-state elevation in GH-related signalling in laboratory models.
CJC-1295 Without DAC (Mod GRF 1-29) Without the albumin-binding modification, this form has a half-life of approximately 30 minutes in experimental systems. It produces a more acute, pulsatile pattern of GH-related signalling that more closely resembles endogenous GHRH activity in research models. It is frequently studied in combination with ghrelin receptor agonists such as ipamorelin to investigate synergistic GH secretagogue pathways.
The selection between these forms in a research context will depend on the specific protocol requirements including desired signalling duration, receptor interaction profile, and experimental observation window.
CJC-1295 vs Sermorelin Research Compound Comparison
Both CJC-1295 and sermorelin are synthetic GHRH analogues studied in laboratory settings, but they differ in several important ways that researchers should be aware of:
Sermorelin is based on GHRH 1-29 without modification. It has a short half-life in experimental systems due to rapid enzymatic degradation, making it more suitable for research protocols studying acute, pulsatile GH release patterns.
CJC-1295 incorporates structural modifications particularly the DAC technology that significantly extend its stability and receptor engagement duration in laboratory models. This makes it more suitable for research protocols requiring sustained GHRH-R activation over extended periods.
Structure-activity relationship studies comparing CJC-1295 with native GHRH and related analogues have demonstrated distinct pharmacological profiles, with CJC-1295 showing enhanced receptor binding affinity and improved receptor residence time in laboratory models.
What to Look for When Sourcing Research Grade CJC-1295 in the UK
For UK-based researchers sourcing CJC-1295 for laboratory use, the following quality indicators are essential:
HPLC-Verified Purity (≥99%): Compound purity is critical for experimental reproducibility. Lower purity compounds introduce analytical variables that can undermine research validity. Always confirm HPLC-verified purity documentation before use.
Batch-Specific Certificate of Analysis (COA): A COA confirms the compound's molecular identity, purity, and batch number. Any credible UK peptide research supplier should provide this documentation on request it is a fundamental requirement for research integrity and laboratory record-keeping.
Lyophilised Format in Sealed Vial: Research grade CJC-1295 should be supplied as a lyophilised powder in a sealed glass research vial. This format ensures maximum stability during storage and transit to UK laboratory addresses.
Correct Storage Specification: CJC-1295 should be stored at −20°C in its sealed vial, protected from moisture and direct light. Improper storage degrades the compound and compromises experimental outcomes.
Clear Research-Only Labelling: All product documentation and labelling should clearly state that the compound is for laboratory research use only, with no claims relating to human or veterinary applications.
Source Research Grade CJC-1295 for Your UK Laboratory Elevr
At Elevr, we supply research grade CJC-1295 for UK laboratories and research institutions. Every vial we dispatch meets the quality standards that UK researchers require for reliable, reproducible experimental work:
- HPLC-verified to ≥99% purity
- Supplied with a batch-specific Certificate of Analysis (COA)
- Dispatched as lyophilised powder in a sealed glass research vial
- Stored and dispatched under controlled conditions for compound integrity during UK delivery
- Clearly labelled for laboratory and research use only
- Fast, discreet UK delivery with secure packaging
Whether you are investigating GHRH receptor signalling, GH secretagogue pathways, metabolic research models, or combined peptide research protocols, Elevr provides a reliable and fully documented supply of high-purity CJC-1295 for your laboratory needs.
We also supply ipamorelin separately for researchers investigating combined GH secretagogue research models.
View Elevr's CJC-1295 Research Compound →
Frequently Asked Questions
Q: What is CJC-1295 used for in research?
CJC-1295 is studied in laboratory settings for its interaction with GHRH receptors and its role in growth hormone signalling pathway research. It has been investigated in GH secretion models, metabolic research, cellular ageing studies, and combined GH secretagogue research involving ipamorelin and other compounds.
Q: What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC incorporates an albumin-binding modification that extends its half-life to approximately 6 to 8 days in research models, enabling sustained GHRH-R activation. CJC-1295 without DAC (Mod GRF 1-29) has a shorter half-life of approximately 30 minutes in experimental systems, producing a more pulsatile GH signalling pattern. Selection depends on the specific requirements of the research protocol.
Q: What is the difference between CJC-1295 and sermorelin in research?
Both are synthetic GHRH analogues, but CJC-1295 incorporates structural modifications — including DAC technology that extend its stability and receptor engagement duration significantly compared to sermorelin. Sermorelin has a shorter half-life in experimental systems, making it more suitable for research protocols studying acute GH release patterns.
Q: Why is CJC-1295 often studied alongside ipamorelin in laboratory research?
CJC-1295 and ipamorelin operate through complementary receptor mechanisms in research models CJC-1295 via GHRH receptors and ipamorelin via ghrelin receptors. Combined laboratory investigations have studied the synergistic effects of dual GH secretagogue pathway activation on downstream signalling endpoints. Elevr supplies both compounds for controlled research use.
Q: What purity should CJC-1295 be for laboratory research?
Research grade CJC-1295 should be verified to ≥99% purity via HPLC analysis. This standard ensures reliable experimental outcomes and reproducibility. Elevr's CJC-1295 meets this specification and is supplied with full batch documentation.
Q: Is Elevr's CJC-1295 suitable for human use or personal supplementation?
No. Elevr's CJC-1295 is supplied strictly for laboratory and research use only. It is not intended for human or veterinary use, consumption, supplementation, or any diagnostic, therapeutic, or cosmetic application. It has not been evaluated by the MHRA or any regulatory authority for clinical use.
This blog post is for informational purposes relating to laboratory research only. Products discussed are supplied strictly for research use and are not intended for human or veterinary use, supplementation, or any diagnostic, therapeutic, or cosmetic purpose. Not evaluated by the MHRA.
